Last reviewed · How we verify
NCT03788785: INTENT
Smoking Tobacco Cessation Integrated Program of Patients Treated for the Head and the Neck Cancer
NA trial testing Experimental arm in Carcinoma, Squamous Cell of Head and Neck in 24 participants. Completed in 20 October 2022.
20 October 2022
Quick facts
| Lead sponsor | Assistance Publique - Hôpitaux de Paris |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 24 |
| Start date | 9 March 2019 |
| Primary completion | 20 October 2022 |
| Estimated completion | 20 October 2022 |
| Sites | 3 locations across France |
Drugs / interventions tested
- Experimental arm
- Control arm
Conditions studied
- Carcinoma, Squamous Cell of Head and Neck — all drugs for Carcinoma, Squamous Cell of Head and Neck →
- Tobacco Use Disorder — all drugs for Tobacco Use Disorder →
Sponsor
Assistance Publique - Hôpitaux de Paris — full company profile →
Who can join
18 and older, any sex, with Carcinoma, Squamous Cell of Head and Neck or Tobacco Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Head and neck squamous cell carcinomas (HNSCCs) arise in the mucosa of the upper aero-digestive tract. They are the 6th most prevalent type of cancer worldwide. The risk related to tobacco is particularly high in the case of HNSCC, as the prevalence of heavy smoking for long periods is high in this population. The investigators' aim is to compare two models: one is a specific model of tobacco cessation intervention designed for health care teams treating patients with HNSCC; the other is the current standard of care for these patients, namely referral to external care after general advice on tobacco cessation. The investigators will evaluate the efficacy of this intervention 12 months after randomization. This intervention will be implemented into otolaryngology (ENT) care by training ENT nurses with a specific program for tobacco cessation delivered to patients diagnosed with HNSCC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03788785
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Experimental arm
Trials testing the same drug.
- NCT06222762 — Effect of Personalized Follow-up in Adapted Physical Activities in Subjects With Chronic Heart Failure. · NA · recruiting
- NCT05581121 — PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer · Phase 3 · recruiting
- NCT04989725 — Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer · Phase 2 · recruiting
- NCT03997435 — FOLFOXIRI With or Without Intensification for Rectal Cancer · Phase 2 · active not recruiting
- NCT02595281 — HE4 as a Relapse Biomarker in Ovarian Cancers · NA · completed
Other recruiting trials for Carcinoma, Squamous Cell of Head and Neck
Currently open trials in the same condition.
- NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting
- NCT03485209 — Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors · Phase 2 · active not recruiting
Other Assistance Publique - Hôpitaux de Paris trials
Trials by the same sponsor.
- NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
- NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
- NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
- NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
- NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03788785 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
- Last refreshed: 25 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03788785.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing